Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 4, Pages 774
Publisher
MDPI AG
Online
2020-04-01
DOI
10.3390/cancers12040774
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia
- (2019) Ming-Chin Chang et al. Frontiers in Immunology
- Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia
- (2019) Leila Hadadi et al. Oncology Research and Treatment
- Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy
- (2019) Beatriz Sanchez-Correa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
- (2019) Yujia Zheng et al. Journal of Translational Medicine
- Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
- (2019) Solène Fernandez et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Accumulation of Tumor-Infiltrating CD49a+ NK Cells Correlates with Poor Prognosis for Human Hepatocellular Carcinoma
- (2019) Haoyu Sun et al. Cancer Immunology Research
- NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans
- (2019) Monica Parodi et al. Frontiers in Immunology
- DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
- (2019) Beatriz Sanchez-Correa et al. Cancers
- Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
- (2019) Ziqing Chen et al. Cancers
- HO‐1 downregulation favors BRAF V600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition
- (2019) Anna L. Furfaro et al. INTERNATIONAL JOURNAL OF CANCER
- Bone marrow microenvironment: The guardian of leukemia stem cells
- (2019) Mohammad Houshmand et al. World Journal of Stem Cells
- Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2
- (2019) Chunxiao Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
- (2019) Atsushi Tanaka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
- (2019) Mattias Carlsten et al. Frontiers in Immunology
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- Molecular targeted therapy: treating cancer with specificity
- (2018) Yeuan Ting Lee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Allelic Polymorphisms of KIR s and HLA s Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML
- (2018) Hiroshi Ureshino et al. Cancer Immunology Research
- Translational insights into gastrointestinal stromal tumor and current clinical advances
- (2018) M L Hemming et al. ANNALS OF ONCOLOGY
- Human AML activates the AHR pathway to impair NK cell development and function
- (2018) Steven D. Scoville et al. BLOOD
- Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
- (2018) Nayoung Kim et al. Frontiers in Immunology
- Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
- (2018) Jorge Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular monitoring in CML: how deep? How often? How should it influence therapy?
- (2018) Naranie Shanmuganathan et al. BLOOD
- Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function
- (2018) Laura Damele et al. Frontiers in Immunology
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
- (2017) Delphine Rea et al. HAEMATOLOGICA
- Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia
- (2017) Qian Jiang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
- (2017) Giuseppe Saglio et al. LEUKEMIA & LYMPHOMA
- Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
- (2017) Delphine Rea et al. HAEMATOLOGICA
- Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia
- (2017) Anne-Sophie Chretien et al. Frontiers in Immunology
- Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
- (2017) Amy Hughes et al. Frontiers in Immunology
- Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors
- (2017) Sheila López-Cobo et al. OncoImmunology
- Innovation in hematology. Perspectives: CML 2016
- (2016) R. Hehlmann HAEMATOLOGICA
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia
- (2016) Mohamed El Missiry et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- Immunological off-target effects of imatinib
- (2016) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
- (2016) Lidia Robert et al. SEMINARS IN IMMUNOLOGY
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
- (2016) Charli Dominguez et al. Cell Death & Disease
- Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
- (2016) Alessia Bottos et al. Nature Communications
- Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function
- (2016) Claudia Manzini et al. Oncotarget
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- Innovation in hematology. Perspectives: CML 2016
- (2016) R. Hehlmann HAEMATOLOGICA
- NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
- (2016) Claudia Cantoni et al. Journal of Immunology Research
- BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system
- (2016) Geoffrey D. Clapp et al. OncoImmunology
- NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
- (2016) Sylvie Rusakiewicz et al. OncoImmunology
- KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
- (2015) D. T. Yeung et al. BLOOD
- Targeted therapy in cancer
- (2015) Apostolia-Maria Tsimberidou CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias
- (2015) Gabriella Pietra et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
- (2015) Koen Schepers et al. Cell Stem Cell
- IL-1β inhibits ILC3 while favoring NK-cell maturation of umbilical cord blood CD34+precursors
- (2015) Paolo Ambrosini et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion
- (2015) Zena Khaznadar et al. JOURNAL OF IMMUNOLOGY
- TLR-Stimulated Neutrophils Instruct NK Cells To Trigger Dendritic Cell Maturation and Promote Adaptive T Cell Responses
- (2015) Rebecca E. Riise et al. JOURNAL OF IMMUNOLOGY
- The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro
- (2015) Jochen Vasold et al. LEUKEMIA RESEARCH
- The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
- (2015) L. Christiansson et al. MOLECULAR CANCER THERAPEUTICS
- Chronic Myeloid Leukemia: Advances in Understanding Disease Biology and Mechanisms of Resistance to Tyrosine Kinase Inhibitors
- (2015) Christopher A. Eide et al. Current Hematologic Malignancy Reports
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML
- (2015) Patrick Schlegel et al. Journal of Immunology Research
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
- (2015) Francesco Spagnolo et al. Oncotarget
- Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma
- (2014) B. Schilling et al. ANNALS OF ONCOLOGY
- Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
- (2014) H. E. Kohrt et al. BLOOD
- Leukemia Propagating Cells Rebuild an Evolving Niche in Response to Therapy
- (2014) Cai-Wen Duan et al. CANCER CELL
- Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma
- (2014) L. Ferrari de Andrade et al. CANCER RESEARCH
- Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse
- (2014) Zena Khaznadar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-1 -releasing human acute myeloid leukemia blasts modulate natural killer cell differentiation from CD34+ precursors
- (2014) C. Vitale et al. HAEMATOLOGICA
- Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
- (2014) K. Stringaris et al. HAEMATOLOGICA
- Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review)
- (2014) David Hoskin et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
- (2014) A. Clayton et al. JOURNAL OF IMMUNOLOGY
- Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D
- (2014) M. Krockenberger et al. JOURNAL OF IMMUNOLOGY
- CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph
- (2014) P. Carrega et al. JOURNAL OF IMMUNOLOGY
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Donor Activating KIR2DS1 in Leukemia
- (2014) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic Approaches
- (2014) Cristina Bottino et al. Frontiers in Immunology
- Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity
- (2013) K. S. Reiners et al. BLOOD
- NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
- (2013) V. Beziat et al. BLOOD
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- NK cells in immunotolerant organs
- (2013) Haoyu Sun et al. Cellular & Molecular Immunology
- Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC
- (2013) Mirna Balsamo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Natural cytotoxicity receptors and their ligands
- (2013) Philip H Kruse et al. IMMUNOLOGY AND CELL BIOLOGY
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2013) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype and antitumor cytotoxicity
- (2013) Tuanjie Li et al. MEDICAL ONCOLOGY
- Targeted Therapies in Hematology and Their Impact on Patient Care: Chronic and Acute Myeloid Leukemia
- (2013) Elias Jabbour et al. SEMINARS IN HEMATOLOGY
- NK cell cytotoxicity mediated by 2B4 and NTB-A is dependent on SAP acting downstream of receptor phosphorylation
- (2013) Stephan Meinke et al. Frontiers in Immunology
- Novel immune modulators used in hematology: impact on NK cells
- (2013) Stephanie Krieg et al. Frontiers in Immunology
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity
- (2012) G. Pietra et al. CANCER RESEARCH
- Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
- (2012) J. Hilpert et al. JOURNAL OF IMMUNOLOGY
- Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
- (2012) S Mustjoki et al. LEUKEMIA
- Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib
- (2012) Yoshiki Hayashi et al. LEUKEMIA & LYMPHOMA
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural killer cell distribution and trafficking in human tissues
- (2012) Paolo Carrega et al. Frontiers in Immunology
- Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function
- (2011) B. Foley et al. BLOOD
- Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
- (2011) Tuanjie Li et al. CANCER LETTERS
- Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition
- (2011) E. Mamessier et al. CANCER RESEARCH
- Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
- (2011) S. Platonova et al. CANCER RESEARCH
- The Evolving War on Cancer
- (2011) Daniel A. Haber et al. CELL
- Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
- (2011) Beatriz Sanchez-Correa et al. IMMUNOLOGY AND CELL BIOLOGY
- Proliferating Cell Nuclear Antigen Is a Novel Inhibitory Ligand for the Natural Cytotoxicity Receptor NKp44
- (2011) B. Rosental et al. JOURNAL OF IMMUNOLOGY
- Role of alloreactive KIR2DS1+ NK cells in haploidentical hematopoietic stem cell transplantation
- (2011) Emanuela Marcenaro et al. JOURNAL OF LEUKOCYTE BIOLOGY
- KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib
- (2011) D Marin et al. LEUKEMIA
- CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
- (2011) S J Coles et al. LEUKEMIA
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Raf kinases in cancer–roles and therapeutic opportunities
- (2011) G Maurer et al. ONCOGENE
- Innate or Adaptive Immunity? The Example of Natural Killer Cells
- (2011) E. Vivier et al. SCIENCE
- Natural Killer Cell Killing of Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia Blasts by Killer Cell Immunoglobulin-Like Receptor–Negative Natural Killer Cells after NKG2A and LIR-1 Blockade
- (2010) Robert Godal et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
- (2010) N. K. Bjorkstrom et al. BLOOD
- The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
- (2010) Julia Salih et al. INTERNATIONAL JOURNAL OF CANCER
- Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome
- (2010) M Carlsten et al. LEUKEMIA
- MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
- (2010) Jennifer AA Gubbels et al. Molecular Cancer
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN- on activation
- (2010) A. De Maria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors
- (2009) Y. T. Bryceson et al. BLOOD
- Regulation of human NK-cell cytokine and chemokine production by target cell recognition
- (2009) C. Fauriat et al. BLOOD
- Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors
- (2009) Miroslaw J. Szczepanski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Natural Killer Cell IFN- Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
- (2009) C. Menard et al. CANCER RESEARCH
- KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C
- (2009) Thorsten Graef et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Preclinical and clinical development of targeted therapy in melanoma: attention to schedule
- (2009) Keith T. Flaherty et al. Pigment Cell & Melanoma Research
- Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
- (2009) M. Balsamo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
- (2008) A. Curti et al. BLOOD
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More